# IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

> **NCT07217301** · PHASE3 · RECRUITING · sponsor: **Fortvita Biologics (USA)Inc.** · enrollment: 600 (estimated)

## Conditions studied

- iO Resistant sqNSCLC

## Interventions

- **DRUG:** IBI363
- **DRUG:** Control Arm

## Key facts

- **NCT ID:** NCT07217301
- **Lead sponsor:** Fortvita Biologics (USA)Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-26
- **Primary completion:** 2028-11-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07217301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07217301, "IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07217301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*